ClinicalTrials.gg
CompletedNCT07151001Updated Nov 6, 2026

Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy

An observational study in Diabetes and Diabetic Retinopathy, sponsored by iHealthScreen Inc. Completed at 1 site in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Primary conditionDiabetic RetinopathyRegistry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetic Retinopathy
Why
  1. The study's listed conditions name Diabetic Retinopathy, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by iHealthScreen Inc · Observational

How we know

Updated Nov 6, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
935
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 54 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Enrollment
13th of 70
935 · median 161
Started
2025
with 11 others
Observational
70 of 267
8 open now
Registered
247th of 267
by date

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 13th largest by enrollment of the 70 observational ones that give a count, is one of 12 that started in 2025, is one of 70 observational ones, and was the 247th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Diabetic Retinopathy studies recruiting now, 61 (66%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 30 take healthy volunteers.

This study: 22 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

In this pivotal trial, the investigators aim to perform a prospective study to find the efficacy of iPredict-DR, an artificial intelligence (AI) based software tool on early diagnosis of Diabetic Retinopathy (DR) in the primary care and endocrinology clinics. DR is one of the leading causes of blindness in the United States and other developed countries. Every individual with diabetes is at risk of DR. It does not show any symptoms until the disease is progressed to advanced stages. If the disease is caught at an early stage, it can be prevented, managed, or treated effectively. Currently, screening for DR is done by the Ophthalmologists, which is limited to areas with limited availability. This is also time-consuming and expensive. All of these can be complemented by automated screening and set up the screening in the primary care clinics.

Read the detailed description

In this pivotal trial, the investigators aim to perform a prospective study to find the efficacy of iPredict-DR, an artificial intelligence (AI) based software tool on early diagnosis of Diabetic Retinopathy (DR) in the primary care and endocrinology clinics. DR is one of the leading causes of blindness in the United States and other developed countries. Every individual with diabetes is at risk of DR. It does not show any symptoms until the disease is progressed to advanced stages. If the disease is caught at an early stage, it can be prevented, managed, or treated effectively. Currently, screening for DR is done by the Ophthalmologists, which is limited to areas with limited availability. This is also time-consuming and expensive. All of these can be complemented by automated screening and set up the screening in the primary care clinics.

American Academy of Ophthalmology has suggested a 5-level DR disease severity scale (No DR, Mild DR, Moderate DR, Severe DR or Proliferative DR) based on the abnormalities in the retina such as microaneurysms, exudates, hemorrhages, intraretinal microvascular abnormalities (IRMA), and neovascularization. Automated screening for Diabetic Retinopathy has a potential to identify people at risk of developing sight-threatening disease and save millions of dollars in healthcare costs. To accomplish this, it is crucial to perform large scale population screening to identify the individuals with mild or early DR and better predict those at risk of developing late stage DR. A system that takes advantage of telemedicine with automated DR screening in reaching the mass populations in both urban and rural areas with the patient convenience is currently not widely available.

Considering this urgent need, iHealthScreen has developed an automated software tool for DR screening which is based on artificial intelligence (AI) and make it widely available in both urban and remote/rural areas and for large-scale screening through a telemedicine platform, and thereby have the potential to prevent blindness in diabetic patients.

03

Conditions studied

  • Diabetes
  • Diabetic Retinopathy

Browse trials for

Keywords

  • Early Diagnosis
  • Screening
04

In context

Diabetic Retinopathy Reclassified

783 studies on the registry are indexed under Diabetic Retinopathy; 145 are open to participants now.

This study's enrollment of 935 is above the median of 173 across 265 observational studies indexed under Diabetic Retinopathy.

Browse Diabetic Retinopathy studies →

Lead sponsor

iHealthScreen Inc is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Compared within Diabetic Retinopathy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Study subjects will be enrolled at primary care practices (internal medicine clinics, endocrinology clinics).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of Subjects: Patients ≥ 22 years of age.
  • Gender of Subjects: Both males and females will be invited to participate.
  • Subjects with diabetes ( level ≥ 6.5).
  • Subjects must be willing and are able to comply with clinic visit, understand the study-related procedures/provisions, and provide signed .

Exclusion criteria

Exclusion Criteria:

  • Unable to understand the study, Our unable to or unwilling to sign the
  • Previously diagnosed with macular edema, any form of diabetic retinopathy, radiation retinopathy, or retinal vein occlusion
  • participants who are experiencing persistent vision loss, blurred vision, or other vision problems that should be evaluated by an eye care provider
  • subjects whose retinal images were used in training, validating, or developing the device
  • Currently participating in another eye study or actively receiving investigational product for DR or DME.
  • A condition that, in the opinion of the investigator, would preclude participation in the study;
  • for imaging by fundus imaging systems used in the study because of to light, recently underwent photodynamic therapy, or was taking medication that causes photosensitivity.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
935 participants (actual)
Patient registry
No

Groups and cohorts

  • One Group

    One Cohort

    Device: No intervention

Interventions

  • DeviceNo intervention

    No intervention. Evaluate the automated DR screening software.

07

What researchers measure

Primary outcomes

  1. mtmDR detected (Referable DR) OR mtmDR not detected (non-referable DR)

    Sensitivity and specificity of identification of referable and non-referable DR for early diagnosis of DR using the iPredict-DR's AI-based DR screening software utilizing color fundus imaging. iPredict-DR can detect non-referable DR (normal retina or mild DR) and referable DR (moderate or severe DR including moderate non-proliferative, proliferative DR and diabetic macular edema) at a similar level of expert ophthalmologists. For this, the healthcare workers will be taking the disc and macula center 45-degree field view images using DRSPlus camera (from iCare Inc.). The output of AI model and ground truth (produced by graders from reading centers) will be compared for image level and subject level accuracy measurements. The worst eye will be considered to define a subject's referability or non-referability to an ophthalmologist. Using the ground truth/gold standard, the sensitivity, specificity, precision, recall, accuracy, F-measure, positive predictive value and negative predictive

    Time frame: 1-year or 2-year

  2. The accuracy of the iPredict-DR software developed by iHealthScreen system in early diagnosis of DR using color retinal photos vs. that of human expert graders

    The accuracy of the iPredict-DR software developed by iHealthScreen system in early diagnosis of DR using color retinal photos vs. that of human expert graders for DR. Performance thresholds were defined at 80.0% for sensitivity and 80.0% for specificity

    Time frame: 1-year or 2-year

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: Yes — In the future we will share the data.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: after 5 years

Access criteria: To be enrolled in the NIH data sharing portal - dbGAP.

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Sep 2025, 8 months.

Of 92 observational studies under Diabetic Retinopathy, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 61. This study's 8 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Jul 2026 → Sep 2025 and completion Jul 2027 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 2, 2025
StartActual
Jan 1, 2025
Primary completionActual
Sep 9, 2025was Jul 2026
CompletionActual
Jun 30, 2026was Jul 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 6, 2026
Primary completion
Jul 31, 2026→Sep 9, 2025 (actual)
Nov 6, 2026
Study completion
Jul 31, 2027→Jun 30, 2026 (actual)
Nov 6, 2026
Enrollment
922 (estimated)→935 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Recruiting→Completed
    Primary completion Jul 31, 2026→Sep 9, 2025 (now actual)
    Study completion Jul 31, 2027→Jun 30, 2026 (now actual)
    Enrollment 922 (estimated)→935 (actual)
    + 4 other changes: verification date, description, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07151001
Lead sponsor
iHealthScreen Inc
Responsible party
Sponsor
First posted
Sep 2, 2025
Start date
Jan 1, 2025
Primary completion
Sep 9, 2025
Completion
Jun 30, 2026
Last update
Nov 6, 2026

Study contacts

Alauddin Bhuiyan, PhD
principal investigator · iHealthScreen Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion